AngioDynamics (ANGO) 10-Q 9 Apr 15 2015 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Feb. 28, 2015	Apr. 06, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	28-Feb-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	ANGO
Entity Registrant Name	ANGIODYNAMICS INC
Entity Central Index Key	1275187
Current Fiscal Year End Date	-26
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		35,917,738

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Income Statement [Abstract]
Net sales	$86,597	$88,150	$266,077	$260,365
Cost of sales	48,746	43,357	134,745	128,107
Gross profit	37,851	44,793	131,332	132,258
Operating expenses
Research and development	6,855	7,045	19,642	20,757
Sales and marketing	19,355	20,700	60,405	61,736
General and administrative	6,917	6,445	22,213	19,542
Amortization of intangibles	5,106	4,248	13,182	12,696
Change in fair value of contingent consideration	-10,044	-4,154	-8,626	-2,481
Acquisition, restructuring and other items, net	18,779	3,016	23,745	7,697
Medical device excise tax	1,034	980	3,105	2,955
Total operating expenses	48,002	38,280	133,666	122,902
Operating income	-10,151	6,513	-2,334	9,356
Other (expenses) income
Interest expense	-859	-917	-2,451	-3,122
Interest income	2		3	0
Other expense	-971	-1,053	-2,950	-2,604
Total other expenses, net	-1,828	-1,970	-5,398	-5,726
Income (loss) before income tax expense (benefit)	-11,979	4,543	-7,732	3,630
Income tax expense (benefit)	-7,717	28	-5,278	-251
Net income (loss)	($4,262)	$4,515	($2,454)	$3,881
Income (loss) per share
Basic (in usd per share)	($0.12)	$0.13	($0.07)	$0.11
Diluted (in usd per share)	($0.12)	$0.13	($0.07)	$0.11
Basic weighted average shares outstanding (in shares)	35,755	35,184	35,568	35,088
Diluted weighted average shares outstanding (in shares)	35,755	35,704	35,568	35,372

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	($4,262)	$4,515	($2,454)	$3,881
Other comprehensive income (loss), before tax:
Unrealized gain (loss) on interest rate swap	133	132	289	-71
Unrealized gain (loss) on marketable securities	-17	-18	-129	-18
Foreign currency translation gain (loss)	-624	106	-728	246
Other comprehensive income (loss), before tax	-508	220	-568	157
Income tax (expense) benefit related to items of other comprehensive income	-43	-42	-59	33
Other comprehensive income (loss), net of tax	-551	178	-627	190
Total comprehensive income (loss), net of tax	($4,813)	$4,693	($3,081)	$4,071

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Feb. 28, 2015	31-May-14
In Thousands, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$19,704	$16,105
Marketable securities	1,682	1,809
Accounts receivable, net of allowances of $2,339 and $1,736 respectively	57,770	61,968
Inventories	68,710	61,234
Deferred income taxes	2,638	4,625
Prepaid income taxes	1,929	510
Prepaid expenses and other	4,859	5,471
Total current assets	157,292	151,722
Property, plant and equipment - at cost, net	58,295	66,590
Other assets	4,060	4,447
Intangible assets, net	186,547	205,256
Goodwill	360,473	360,473
Deferred income taxes, long-term	16,469	10,403
TOTAL ASSETS	783,136	798,891
CURRENT LIABILITIES
Accounts payable	21,696	32,895
Accrued liabilities	19,946	17,251
Income Taxes Payable	677	689
Current portion of long-term debt	7,500	5,000
Current portion of contingent consideration	9,868	10,918
Total current liabilities	59,687	66,753
Long-term debt, net of current portion	141,410	137,660
Deferred income taxes, long-term	1,146	1,146
Contingent consideration, net of current portion	37,137	56,413
Other long-term liabilities	0	84
Total liabilities	239,380	262,056
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, par value $.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $.01 per share, 45,000,000 shares authorized; issued 36,023,413 and 35,442,004 shares and outstanding 35,881,108 and 35,299,699 shares at February 28, 2015 and May 31, 2014, respectively	360	353
Additional paid-in capital	518,349	508,354
Retained earnings	29,047	31,501
Treasury stock, 142,305 shares, at cost	-2,104	-2,104
Accumulated other comprehensive loss	-1,896	-1,269
Total stockholders’ equity	543,756	536,835
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$783,136	$798,891

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Feb. 28, 2015	31-May-14
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$2,339	$1,736
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	36,023,413	35,442,004
Common stock, shares outstanding	36,023,413	35,442,004
Treasury stock, shares	142,305	142,305

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014
Cash flows from operating activities:
Net income (loss)	($2,454)	$3,881
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	22,776	21,113
Stock based compensation	4,389	4,022
Change in fair value of contingent consideration	-8,626	-2,481
Deferred income taxes	-4,138	1,700
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	6,400	0
Impairment of Long-Lived Assets Held-for-use	9,188	0
Bad debt expense	659	281
Tax effect on exercise of stock options and issuance of performance shares	0	-146
Other	-70	-50
Amortization of acquired inventory basis step-up	0	150
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	3,535	-9,668
Inventories	-7,476	-3,491
Prepaid expenses and other assets	-2,319	-2,958
Accounts payable, accrued and other liabilities	-6,428	2,821
Net cash provided by operating activities	15,436	15,174
Cash flows from investing activities:
Additions to property, plant and equipment	-11,038	-9,003
Acquisition of business, net of cash acquired	0	-4,169
Acquisition of intangibles	-1,004	-180
Payments to Acquire Marketable Securities	0	-25
Proceeds from sale or maturity of marketable securities	0	353
Net cash used in investing activities	-12,042	-13,024
Cash flows from financing activities:
Proceeds from issuance of and borrowings on long-term debt	15,000	141,410
Repayment of long-term debt	-8,750	-145,000
Deferred financing costs on long-term debt	0	677
Payment of contingent consideration previously established in purchase accounting	-11,222	-14,597
Proceeds from exercise of stock options and employee stock purchase plan	5,613	2,208
Net cash provided by (used in) financing activities	641	-16,656
Effect of exchange rate changes on cash and cash equivalents	-436	86
Increase (decrease) in cash and cash equivalents	3,599	-14,420
Cash and cash equivalents at beginning of period	16,105	21,802
Cash and cash equivalents at end of period	19,704	7,382
Supplemental disclosure of non-cash investing and financing activities:
Contractual obligations for acquisition of intangibles and business	349	4,970
Contractual obligations for acquisition of fixed assets	$211	$1,200

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Treasury Stock [Member]
Beginning Balance at May. 31, 2014	$536,835,000	$353,000	$508,354,000	$31,501,000	($1,269,000)	($2,104,000)
Beginning Balance,Treasury Shares at May. 31, 2014	-142,305
Beginning Balance, Shares at May. 31, 2014		35,442,004
Net income (loss)	-2,454,000			-2,454,000
Exercise of stock options	4,195,000	3,000	4,192,000
Exercise of stock options, Shares		321,134
Purchase of common stock under ESPP	1,416,000	2,000	1,414,000
Purchase of common stock under ESPP, Shares		119,001
Issuance of performance shares	2,000	2,000
Issuance of performance shares, Shares		141,274
Stock based compensation	4,389,000		4,389,000
Other comprehensive income, net of tax	-627,000				-627,000
Ending Balance at Feb. 28, 2015	$543,756,000	$360,000	$518,349,000	$29,047,000	($1,896,000)	($2,104,000)
Ending Balance,Treasury Shares at Feb. 28, 2015	-142,305					-142,305
Ending Balance, Shares at Feb. 28, 2015		36,023,413

Consolidated_Financial_Stateme

Consolidated Financial Statements	9 Months Ended
	Feb. 28, 2015
Accounting Policies [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS
	The consolidated balance sheet as of February 28, 2015, the consolidated statement of stockholders’ equity and consolidated statement of cash flows for the nine months ended February 28, 2015, the consolidated statements of income (loss) and the consolidated statements of comprehensive income (loss) for the three and nine months ended February 28, 2015 and 2014 have been prepared by us without audit. The consolidated balance sheet as of May 31, 2014 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended February 28, 2015 (and for all periods presented) have been made.
	Certain information and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these unaudited interim consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K/A for the fiscal year ended May 31, 2014. Our most significant accounting policies are disclosed in Note A to the consolidated financial statements included in the aforementioned Form 10-K/A for the fiscal year ended May 31, 2014. The results of operations in the fiscal periods ended February 28, 2015 and 2014 are not necessarily indicative of the operating results for the respective full fiscal years.
	The unaudited interim consolidated financial statements for the three and nine months ended February 28, 2015 and February 28, 2014 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries, collectively, the “Company”. All intercompany balances and transactions have been eliminated.
	During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items. Refer to Note P for further details.
	Recent Developments
	In the third quarter of 2015, the Company initiated a voluntary recall of the Morpheus Smart PICC CT product and concurrently discontinued the product line. The Company accrues for costs of product recalls, customer sales allowances and other related costs based on management's best estimates when it is probable a charge or liability has been incurred, management commits to a plan, and/or regulatory requirement dictates the need for corrective or preventive action and the amount of loss can be reasonably estimated. Product recall related charges, recognized in cost of sales, include materials, costs to address identified issues, deployment costs such as labor, freight, product disposal and other customer accommodations. Customer sales allowances charges, recognized as a reduction of Net sales, include amounts to be offered to customers, which may be used as a credit for transition to alternative technology. Other costs associated with the recall are recognized in acquisition, restructuring and other items, net. These costs include disposals of fixed assets, storage costs, commissions and cancellation fees. Results for the quarter ended February 28, 2015 include a $0.2 million reserve recorded as a reduction in Net sales, a $5.0 million write-off of inventory in Cost of sales and $0.9 million of other costs in acquisition, restructuring and other items, net.
	In the third quarter of 2015, the Company made a decision to discontinue investment in and development of an Automated Power Injector, a product the Company anticipated launching to address a need in the fluid management market. This decision was made after an evaluation of the anticipated opportunity, risks and costs necessary to complete the regulatory and development path required to launch the product. As a result of this decision, and the absence of anticipated cash flow from the product and existing fixed assets, the Company recorded an $8.2 million impairment charge, representing a full impairment on the fixed assets. This project termination decreased the long-term sales forecasts for products sold with the NAMIC brand. At the time of the Navylist acquisition in fiscal 2012 the Company, as part of purchase accounting, recorded a $28.6 million indefinite-lived intangible associated with this trademark. Primarily as a result of removing expected sales of the Automated Power Injector, the value of the trademark was deemed to be impaired, resulting in a $6.4 million charge during the three and nine months ended February 28, 2015. Refer to Note D for further details.
	On March 2, 2015, the Company filed an 8-K stating that it executed a non-binding letter of intent to enter into a strategic relationship with privately-held EmboMedics Inc., which develops injectable and resorbable embolic microspheres. On April 9, 2015 the Company entered into a License, Distribution, Manufacturing and Purchase Option Agreement with EmboMedics Inc, subject to certain approvals by EmboMedics shareholders.
	Under the terms of the agreement, AngioDynamics receives an exclusive worldwide license to market and sell, upon regulatory clearances, EmboMedics’ microsphere technology. AngioDynamics will also control manufacturing of the products. AngioDynamics will make an initial $2.0 million equity investment in EmboMedics through the purchase of preferred stock. The Company may make an additional $9.0 million in equity, as well as milestone driven investments, and can execute an exclusive option to acquire EmboMedics, based on the achievement of certain milestones.

Acquisitions

Acquisitions	9 Months Ended
	Feb. 28, 2015
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS
	Acquisition of Clinical Devices
	On August 15, 2013 we acquired all the outstanding shares of capital stock of Clinical Devices, B.V., exclusive distributor of our fluid management products in the Netherlands. The stock purchase agreement provided for the payment of $3.7 million in cash at closing, which was subject to a working capital adjustment and $400,000 holdback, plus future earn out consideration payable in cash. Earn out consideration was based on our net sales of the fluid management products during the five quarters following the closing as well as milestone payments for achieving regulatory approvals of certain in process research and development for a next-generation tip location technology. The holdback and net sales related amounts were paid in September 2014. The total purchase consideration of $8.7 million included the upfront payment and the estimated fair value of contingent consideration at the time of acquisition of $5.0 million.
	Goodwill recorded as a result of the acquisition was approximately $4.8 million and is not deductible for tax purposes. Intangible assets acquired, other than goodwill, totaled approximately $5.1 million, of which $3.6 million has been identified as in-process research and development, $1.4 million as customer relationships (15-year estimated useful life) and $70,000 as trademarks (5-year estimated useful life). We also recorded a deferred tax liability of $1.2 million.
	The acquisition has been accounted for as a purchase and, accordingly, we have included the results of operations in the financial statements effective August 15, 2013. The pro forma effects of the acquisition on our income statement and balance sheet were not material.

Inventories

Inventories	9 Months Ended
	Feb. 28, 2015
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 28, 2015 and May 31, 2014, inventories consisted of the following:
		Feb 28, 2015		31-May-14
		(in thousands)
	Raw materials	$	28,155	$	24,734
	Work in process	12,050		11,992
	Finished goods	28,505		24,508
	Inventories	$	68,710	$	61,234

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Feb. 28, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS
	Intangible assets other than goodwill and indefinite lived intangible assets are amortized over their estimated useful lives, which range between two and fifteen years, on either a straight-line basis or proportionately to the benefit being realized. We periodically review the estimated useful lives of our intangible assets and review such assets for impairment, based on estimated future cash flows, whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. If an intangible asset is considered to be impaired, the amount of the impairment will equal the excess of the carrying value over the fair value of the asset.
	Goodwill and intangible assets that have indefinite useful lives are not amortized, but rather, are tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. Goodwill and intangible assets have been recorded at either incurred or allocated costs based on respective fair market values at the date of acquisition.
	For goodwill, the impairment test requires a comparison of the estimated fair value, based on future cash flows, of the reporting unit to which the goodwill is assigned to the sum of the carrying value of the assets and liabilities of that unit. If the sum of the carrying value of the assets and liabilities of a reporting unit exceeds the fair value of the reporting unit, the carrying value of the reporting unit’s goodwill is reduced to its implied fair value through an adjustment to the goodwill balance, resulting in an impairment charge.
	We consider our business to be a single operating segment entity - the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery.
	To determine fair value, we considered two market-based approaches and an income approach. Under the market-based approaches, we utilized information regarding our own as well as publicly available industry information to determine earnings multiples and sales multiples. Under the income approach, we determined fair value based on estimated future cash flows of the reporting unit, discounted by an estimated weighted-average cost of capital, which reflects the overall level of inherent risk of a reporting unit and the rate of return an outside investor would expect to earn. We determined the discounted cash flow as the best indicator to determine fair value and therefore assigned a weight of 75% with the remaining 25% assigned to the market approach.
	Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, operating margins, discount rates and future market conditions, among others. These assumptions are highly sensitive and changes in these estimates could result in impairment. Solely for purposes of establishing inputs for the fair value calculations, we assumed that the current economic conditions would continue through fiscal year 2015. In addition, we applied gross margin assumptions, showing some improvement over historical trends, at various revenue levels and used a capitalization rate of 8.0% to calculate the terminal value of the reporting unit. In addition, we used a discount rate of 12% to calculate the fair value of our reporting unit.
	We completed our annual goodwill impairment test as of December 31, 2014. At December 31, 2014, our reporting unit is the same as our reportable segment. Our assessment of goodwill impairment indicated that the fair value of our reporting unit exceeded its carrying value and therefore goodwill was not impaired. The fair value of our reporting unit exceeded its carrying value by 18%. The fair value of the reporting unit was reconciled to our current stock market capitalization as of December 31, 2014.
	Since early November 2008, our stock market capitalization has at times been lower than our shareholders’ equity or book value. However, our reporting unit has continued to generate significant cash flows from operations, and we expect to continue to do so in fiscal 2015 and beyond. Furthermore, we believe that a reasonable potential buyer would offer a control premium for our business that would adequately cover the difference between our stock market capitalization and our book value.
	We also completed our annual indefinite lived asset (NAMIC trademark) test as of December 31, 2014 using the income approach to determine fair value. Under this approach, the relief from royalty method was applied using a 3% long-term growth rate, a 3% royalty rate and a 12% discount rate. Our assessment of the NAMIC trademark indicated that the carrying value exceeded the fair value by $6.4 million; therefore, the asset was impaired and a $6.4 million impairment charge was taken during Q3 2015. This charge is included in Acquisition, restructuring and other items on our consolidated statement of profit (loss). We also re-evaluated the NAMIC trademark at February 28, 2015 and determined that it is no longer an indefinite-lived intangible. We have assigned it a remaining useful life of 12 years, consistent with customer relationships, and we will begin amortization in the fourth quarter of 2015.
	Even though we determined that there was no goodwill impairment as of December 31, 2014, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal factors or business climate, an adverse action or assessment by a regulator, unanticipated competition, a material negative change in relationships with significant customers, strategic decisions made in response to economic or competitive conditions, loss of key personnel or a more-likely-than-not expectation that the reporting unit or a significant portion of the reporting unit will be sold or disposed of, would require an interim assessment for the reporting unit prior to the next required annual assessment as of December 31, 2015.
	It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material. Events that could, in the future, result in impairment include, but are not limited to, declining sales for a significant product or in a significant geographic region.
	There were no adjustments to goodwill for the nine months ended February 28, 2015.
	As of February 28, 2015 and May 31, 2014, intangible assets consisted of the following:
		28-Feb-15
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	148,776	$	(38,724	)	$	110,052	10.2
	Customer relationships	86,397		(41,770		)	44,627		12
	Trademark-NAMIC	22,200		—			22,200		12
	Licenses	7,913		(5,709		)	2,204		8.7
	Trademarks	6,345		(2,481		)	3,864		8
	In-process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	276,131	$	(89,584	)	$	186,547
		31-May-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,298	$	(32,930	)	$	117,368	10.2
	Customer relationships	86,645		(37,848		)	48,797		11.9
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	Licenses	7,639		(5,211		)	2,428		8.4
	Trademarks	6,345		(1,882		)	4,463		8
	In process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	284,027	$	(78,771	)	$	205,256

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Feb. 28, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES
	As of February 28, 2015 and May 31, 2014, accrued liabilities consisted of the following:
		Feb 28, 2015		31-May-14
		(in thousands)
	Payroll and related expenses	$	10,535	$	8,114
	Royalties	2,149		2,620
	Accrued severance	472		765
	Sales and franchise taxes	697		1,327
	Interest rate swap liability	267		555
	Accrued taxes payable	1,808		371
	Other	4,018		3,499
		$	19,946	$	17,251

Long_Term_Debt

Long Term Debt	9 Months Ended
	Feb. 28, 2015
Debt Disclosure [Abstract]
Long Term Debt	LONG TERM DEBT
	On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.
	The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).
	The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five. Interest on both the Term Loan and Revolving Facility are based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.5% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.2% to 0.35% per annum on the unused portion.
	Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors.
	We have entered into an interest rate swap agreement, (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement. The Swap matures during 2016.
	On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Former Credit Agreement. As of February 28, 2015, $92.5 million and $56.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated adjusted EBITDA minus consolidated capital expenditures to consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated adjusted EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of February 28, 2015.

Income_Taxes

Income Taxes	9 Months Ended
	Feb. 28, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	The following table presents the components of income tax expense(benefit) for the three and nine months ended February 28, 2015 and 2014 (in thousands of dollars):
		Three Months Ended						Nine Months Ended
		28-Feb-15			28-Feb-14			28-Feb-15			28-Feb-14
	Income (loss) before Income Taxes	$	(11,979	)	$	4,543		$	(7,732	)	$	3,630
	Less discrete book income (expense):
	Non taxable portion of revaluation of contingent consideration	9,229			5,000			9,229			5,000
	Taxable portion of revaluation of contingent consideration	1,323			—			1,323			—
	Morpheus product recall and discontinuance	(6,145		)	—			(6,145		)	—
	Impairment of Automated Power Injector fixed asset	(8,200		)	—			(8,200		)	—
	Impairment of indefinite-lived intangible asset	(6,400		)	—			(6,400		)	—
	Ordinary income (loss) before income taxes	(1,786		)	(457		)	2,461			(1,370		)
	Income tax expense (benefit) based on ordinary income (loss) at estimated tax rates of 51.8% and 42.9% for the three and nine months ended February 28, 2015 and February 28, 2014, respectively	$	(461	)	$	(233	)	$	1,276		$	(587	)
	Discrete tax expense (benefit):
	Morpheus product recall and discontinuance	(2,243		)	—			(2,243		)	—
	Impairment of Automated Power Injector fixed asset	(2,993		)	—			(2,993		)	—
	Taxable gain on revaluation of contingent consideration liability	483			—			483			—
	Impairment of indefinite-lived intangible asset	(2,336		)	—			(2,336		)	—
	Adjustment for elimination of the ASC 718 APIC pool	289			62			974			123
	Retroactive renewal of the Research and Experimentation credit	(519		)	—			(519		)	—
	Adjustment to fully reserved capital losses	—			43			—			43
	Adjustments to prior period tax liabilities	63			156			80			170
	Total income tax expense (benefit)	$	(7,717	)	$	28		$	(5,278	)	$	(251	)
	The third quarter estimated effective tax rate prior to discrete items was 51.8% in 2015, as compared to 42.9% for the same period in 2014. The tax rates are greater than the 35% US statutory tax rate primarily due to the impact of non-deductible items (such as the non-deductible portion of meals and entertainment and non-deductible interest on contingent payments) caused by the limited ordinary income (loss) before income taxes in 2015 and 2014.
	Our ASC 718 APIC pool was depleted in the quarter ended November 30, 2013. Prior to its depletion, the APIC pool was reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting. Due to its depletion we recorded a discrete tax expense in the three and nine months ended February 2015 and 2014, as noted in the above table.
	During the fiscal third quarter of 2015, the Tax Increase Prevention Act of 2014 (H.R. 5771) was enacted and retroactively extended the research credit from January 1, 2014 to December 31, 2014. Accordingly, the retroactive benefit related to this renewal has been reflected in our third quarter results.
	We have recorded a net deferred tax asset in the US of $19.1 million which includes the benefit of $139 million of loss carryforwards recorded in business acquisitions, which expire as follows:
	Expiration Date	NOL Available (in thousands)
	FY 2017	$	802
	FY 2019	11,898
	FY 2020	8,128
	FY 2022	7,526
	FY 2023	2,346
	FY 2027	20,167
	FY 2028	22,527
	FY 2029	27,684
	FY 2030	28,043
	FY 2031	5,647
	FY 2032	600
	FY 2033	3,389
	The Company’s analysis of the need for a valuation allowance considered that the Company has incurred a cumulative loss in the U.S. over the three year period ending February 28, 2015. A majority of the cumulative loss has been caused by the charges associated with the product recall and discontinuance and the impairment of fixed and intangible assets recorded in the quarter end February 28, 2015, as well as restructuring and integration expenses in the period since the acquisition of Navilyst Medical in May 2012. We anticipate a return to profitability in fiscal 2016. Consideration has also been given to our history of not having Federal tax loss carryforwards expire unused, as well as the period over which the net deferred tax assets can be realized, including the expiration of our loss carryforwards as presented in the table above and IRC Section 382 limitations.
	Based on our assessment, it appears more likely than not that our U.S. net deferred tax asset will be realized through future taxable earnings, the reversal of existing taxable temporary differences, and tax planning strategies. Accordingly no valuation allowance has been recorded on this net asset. We will continue to assess the need for a valuation allowance in the future.
	If future results are less than projected in the U.S. and if tax planning alternatives do not offset those effects, a valuation allowance may be required to reduce the deferred tax asset, which could have a material impact on our results of operations in the period in which it is recorded. While the net deferred tax asset at February 28, 2015 is $19.1 million, if the Company were required to record a valuation allowance it could be greater than this amount due to deferred tax liabilities related to intangibles that have an indefinite reversal period.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Feb. 28, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION
	We have two stock-based compensation plans that provide for the issuance of up to approximately 5.8 million shares of common stock. The 2004 Stock and Incentive Award Plan (the "2004 Plan") provides for the grant of incentive options to our employees and for the grant of non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other incentive awards to our employees, directors and other service providers. We also have an employee stock purchase plan.
	For the quarters ended February 28, 2015 and 2014, share-based payment expense was $1.5 million and $1.6 million, respectively.
	In the third quarter of fiscal year 2015 and 2014, the company granted stock options and restricted stock units under the 2004 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of our shares on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.
	In the first quarter of fiscal year 2015 and the second quarter of 2014, the company granted performance share awards under the 2004 Plan to certain employees. The awards may be earned by achieving relative performance levels over the three year requisite service period. The performance criteria are based on the total shareholder return ("TSR") of the company's common stock relative to the TSR of the common stock of a pre-defined industry peer-group. The fair value of these awards are based on the closing trading value of our shares on the date of grant and use a Monte Carlo simulation model.
	As of February 28, 2015, there were $12.1 million of unrecognized compensation expenses related to share-based payment arrangements. These costs are expected to be recognized over a weighted-average period of approximately four years. The company has sufficient shares to satisfy expected share-based payment arrangements.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Feb. 28, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE
	Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not antidilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.
	The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2015 and 2014 (in thousands):
		Three Months Ended		Nine Months Ended
		Feb 28, 2015	Feb 28, 2014	Feb 28, 2015	Feb 28, 2014
	Basic	35,755	35,184	35,568	35,088
	Effect of dilutive securities	—	520	—	284
	Diluted	35,755	35,704	35,568	35,372
	Securities excluded as their inclusion would be anti-dilutive	362	677	674	2,306

Segment_and_Geographic_Informa

Segment and Geographic Information	9 Months Ended
	Feb. 28, 2015
Segment Reporting [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION
	We consider our business to be a single operating segment entity engaged in the development, manufacture and sale on a global basis of medical devices for vascular access, peripheral vascular disease, oncology and surgery. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.
	The table below summarizes net sales by product category (in thousands of dollars):
		Three Months Ended				Nine Months Ended
		Feb 28, 2015		Feb 28, 2014		Feb 28, 2015		Feb 28, 2014
	Net sales
	Peripheral Vascular	$	46,195	$	47,358	$	142,996	$	141,718
	Vascular Access	26,400		27,259		80,793		78,113
	Oncology/Surgery	13,066		11,968		39,062		35,692
	Supply Agreement	936		1,565		3,226		4,842
	Total	$	86,597	$	88,150	$	266,077	$	260,365
	The table below presents net sales by geographic area based on external customer location (in thousands of dollars):
		Three Months Ended				Nine Months Ended
		Feb 28, 2015		Feb 28, 2014		Feb 28, 2015		Feb 28, 2014
	Net sales
	United States	$	68,410	$	69,814	$	208,848	$	206,466
	International	17,251		16,771		54,003		49,057
	Supply Agreement	936		1,565		3,226		4,842
	Total	$	86,597	$	88,150	$	266,077	$	260,365

Fair_Value

Fair Value	9 Months Ended
	Feb. 28, 2015
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE
	Our financial instruments include cash and cash equivalents, accounts receivable, marketable securities, accounts payable, interest rate swap agreement and contingent earn outs. The carrying amount of cash and cash equivalents, accounts receivable, marketable securities and accounts payable approximates fair value due to the immediate or short-term maturities. The interest rate swap agreement has been recorded at its fair value based on a valuation received from an independent third party. The contingent earn out has been recorded at fair value using the income approach.
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This policy establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value which are provided in the table below.
	Level 1 Quoted prices in active markets for identical assets or liabilities. Level 1 assets include bank time deposits, money market funds, mutual funds and U.S. Treasury securities that are traded in an active exchange market.
	Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets include US government securities and corporate bonds. When quoted market prices are unobservable, we obtain pricing information from an independent pricing vendor. The pricing vendor uses various pricing models for each asset class that are consistent with what other market participants would use. The inputs and assumptions to the model of the pricing vendor are derived from market observable sources including: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids, offers, and other market-related data. Since many fixed income securities do not trade on a daily basis, the methodology of the pricing vendor uses available information as applicable such as benchmark curves, benchmarking of like securities, sector groupings, and matrix pricing. The pricing vendor considers all available market observable inputs in determining the evaluation for a security. Thus, certain securities may not be priced using quoted prices, but rather determined from market observable information. These investments are included in Level 2 and primarily comprise our portfolio of corporate and government fixed income securities. Additionally included in Level 2 are interest rate swap agreements which are valued using a mid-market valuation model.
	Level 3 Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category currently includes the auction rate securities where independent pricing information was not able to be obtained and the contingent earn out. Our investments in auction-rate securities were classified as Level 3 as quoted prices were unavailable since these auction rate securities issued by New York state and local government authorities failed auction. Due to limited market information, we utilized a discounted cash flow (“DCF”) model to derive an estimate of fair value for all periods presented. The assumptions used in preparing the DCF model included estimates with respect to the amount and timing of future interest and principal payments, forward projections of the interest rate benchmarks, the probability of full repayment of the principal considering the credit quality and guarantees in place, and the rate of return required by investors to own such securities given the current liquidity risk associated with auction-rate securities. The contingent earn outs were valued utilizing a discounted cash flow method as detailed below.
	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2015 and May 31, 2014 (in thousands of dollars):
		Fair Value Measurements using								Fair Value at February 28, 2015
		inputs considered as:
		Level 1			Level 2			Level 3
	Financial Assets
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,682	$	1,682
	Total	—			—			1,682		1,682
	Total Financial Assets	$	—		$	—		$	1,682	$	1,682
	Financial Liabilities
	Interest rate swap agreements	$	—		$	267		$	—	$	267
	Contingent liability for acquisition earn out	—			—			47,005		47,005
	Total Financial Liabilities	$	—		$	267		$	47,005	$	47,272
		Fair Value Measurements using								Fair Value at May 31, 2014
		inputs considered as:
		Level 1			Level 2			Level 3
	Financial Assets
	Cash equivalents
	Money market funds	$	445		$	—		$	—	$	445
	Total	$	445		$	—		$	—	$	445
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,809	$	1,809
	Total	—			—			1,809		1,809
	Total Financial Assets	$	445		$	—		$	1,809	$	2,254
	Financial Liabilities
	Interest rate swap agreements	$	—		$	555		$	—	$	555
	Contingent liability for acquisition earn out	—			—			67,331		67,331
	Total Financial Liabilities	$	—		$	555		$	67,331	$	67,886
	There were no transfers in and out of Level 1, 2 and 3 measurements for the nine months ended February 28, 2015.
	The table below presents the changes in fair value components of Level 3 instruments in the nine months ended February 28, 2015 (in thousands of dollars):
		Financial Assets			Financial Liabilities
		Fair Value Measurements			Fair Value Measurements
		Using Significant			Using Significant
		Unobservable Inputs			Unobservable Inputs
		(Level 3)			(Level 3)
	Balance, May 31, 2014	$	1,809		$	67,331
	Change in present value of contingent consideration (1)	—			(8,626		)
	Currency (gain) loss from remeasurement	—			(478		)
	Included in other comprehensive income	(127		)	—
	Contingent consideration payments	—			(11,222		)
	Balance, February 28, 2015	$	1,682		$	47,005
	(1) Change in present value of contingent consideration is included in earning and comprised of changes in estimated earn out payments based on projections of company performance and the amortization of the present value discount.
	Contingent Liabilities for Acquisition Earn Outs
	Certain of our business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent milestone consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the consolidated statements of income. We measure the initial liability and remeasure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements.
	Contingent consideration liabilities fair value is determined using a discounted cash flow model applied to projected net sales, using probabilities of payment and projected payment dates. Projected net sales are based on our internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future.
	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2015 (in thousands of dollars):
		Fair value at			Valuation
		Feb 28, 2015			Technique		Unobservable Input	Range
	Revenue based payments	$	44,383		Discounted cash flow		Discount rate	4%
							Probability of payment	75-100%
							Projected fiscal year of payment	2016 - 2022
	Milestone based payments	2,622			Discounted cash flow		Discount rate	16%
							Probability of payment	75-100%
							Projected fiscal year of payment	2017
	Total	$	47,005
	At February 28, 2015, the estimated potential amount of undiscounted future contingent consideration that we expect to pay as a result of all completed acquisitions is approximately $54.2 million. The milestones associated with the contingent consideration must be reached in future periods ranging from fiscal years 2016 to 2022 in order for the associated consideration to be paid.

Marketable_Securities

Marketable Securities	9 Months Ended
	Feb. 28, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	MARKETABLE SECURITIES
	Marketable securities, which are principally government agency bonds, auction rate investments and corporate commercial paper, are classified as “available-for-sale securities” in accordance with authoritative guidance issued by FASB and are reported at fair value, with unrealized gains and losses excluded from operations and reported as accumulated other comprehensive income (loss), net of the related tax effects, in stockholders’ equity. Cost is determined using the specific identification method. We hold investments in auction rate securities in order to generate higher than typical money market rate investment returns. Auction rate securities typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids and, in such cases, the auction fails and we may be unable to liquidate our position in the securities in the near term. As of February 28, 2015 and May 31, 2014, we had $1.7 million and $1.8 million, respectively, in investments in two auction rate securities issued by New York state and local government authorities that failed auctions. The authorities are current in their interest payments on the securities.
	As of February 28, 2015 and May 31, 2014, marketable securities consisted of the following (in thousands of dollars):
	As of February 28, 2015	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(143	)	$	1,682
		$	1,825	$	—	$	(143	)	$	1,682
	As of May 31, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(16	)	$	1,809
		$	1,825	$	—	$	(16	)	$	1,809

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Feb. 28, 2015
Commitments and Contingencies Disclosure [Abstract]
Litigation	COMMITMENTS AND CONTINGENCIES
	Legal Proceedings
	The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, regulatory and environmental matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation.
	AngioDynamics v. biolitec
	On January 2, 2008, we commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. biolitec, Inc. In this action, we sought judgment against biolitec for defense and indemnification in two lawsuits which we previously settled. Our claims arise out of a Supply and Distribution Agreement (“SDA”) entered into with biolitec on April 1, 2002. On September 27, 2011, the U.S. District Court granted key portions of our motion for summary judgment in our legal case against biolitec. The Court also dismissed biolitec’s counterclaims against us. The court denied one portion of our summary judgment motion, which sought to recover additional costs from biolitec, leaving this for adjudication at trial. On November 8, 2012, the Court granted partial judgment to us in the amount of $23.2 million. Biolitec appealed this judgment. On August 23, 2013, the U.S. Court of Appeals for the Second Circuit dismissed biolitec’s appeal.
	In October 2009, we commenced an action in the United States District Court for the District of Massachusetts entitled AngioDynamics, Inc. v. biolitec AG and Wolfgang Neuberger. The Complaint in this action was amended in March 2010. This action seeks to recover against biolitec, Inc.’s parent entities and CEO for tortuously interfering with biolitec, Inc.’s contractual obligation to defend and indemnify us, and also seeks to pierce the corporate veil of biolitec, Inc. and to invalidate certain alleged fraudulent transfers in order to hold biolitec, Inc.’s parent entities jointly and severally liable for the alleged breach of the SDA. On September 13, 2012, the Massachusetts Court granted our request for a preliminary injunction prohibiting the downstream merger of biolitec AG with its Austrian subsidiary. On April 1, 2013, the U.S. Court of Appeals for the First Circuit affirmed the preliminary injunction. On January 14, 2014, the District Court entered judgment in our favor as to liability. On March 18, 2014, the District Court entered judgment in our favor against Biolitec AG, Biomed Technology Holdings, Ltd., and Wolfgang Neuberger, jointly and severally, in the amount of $74.9 million. The defendants have appealed this judgment.
	August 29, 2013, we became co-plaintiffs in an adversary proceeding in the United States Bankruptcy Court for the District of New Jersey entitled Cyganowski, Trustee, et al. v. Biolitec U.S., Inc., et al. In this action, we assert claims of conversion, unjust enrichment, tortious interference, and unfair competition against various biolitec entities for alleged violation of Bankruptcy Court settlement and sale orders under which we acquired certain assets of Biolitec, Inc. On September 3, 2013, we, along with our co-plaintiff, obtained a temporary restraining order against the defendants in this action. On January 22, 2015, the Bankruptcy Court entered a permanent injunction on our behalf for an additional two years.
	C.R. Bard, Inc. v. AngioDynamics, Inc.
	On January 11, 2012, C.R. Bard, Inc. filed a suit in the United States District Court of Utah claiming certain of our implantable port products infringe on three U.S. patents held by Bard (the "Utah Action"). Bard is seeking unspecified damages and other relief. The Court denied Bard’s motion for pre-trial consolidation with separate actions it filed on the same day against Medical Components, Inc. and Smiths Medical ASD, Inc., but had asked for supplemental briefing on the issue of whether to conduct a common Markman hearing. Meanwhile, we filed petitions for reexamination in the US Patent and Trademark Office ("PTO") which seek to invalidate all three patents asserted in the litigation. Our petitions have been granted and 40 of 41 patent claims have been and remain rejected. The Patent Office has issued a Final Rejection of all the claims subject to reexamination and Bard has filed appeals. The parties have completed briefing on the appeals and are awaiting further direction by the Board of Appeals and Interferences. The case has been stayed pending final resolution of the PTO process. We believe these claims are without merit and intend to defend them vigorously. We have not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
	On March 10, 2015, C.R. Bard, Inc. and Bard Peripheral Vascular, Inc. filed suit in the United States District Court for the District of Delaware claiming certain of our implantable port products infringe three Bard patents (the "Delaware Action"). Bard is seeking unspecified damages and other relief; and the patents asserted in the Delaware Action are different than those asserted in the Utah Action.
	By stipulation, we have until June 1, 2015 to answer, move or otherwise respond to the complaint in the Delaware Action. We believe these claims are without merit and intend to defend them vigorously. We have not recoded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.
	BTG International, Inc.
	We received a subpoena from the U.S. Department of Justice (the “DOJ”) requesting documents in relation to a purported criminal investigation the DOJ is conducting regarding BTG International, Inc.’s LC Bead® product beginning in 2003.  RITA Medical Systems and AngioDynamics, Inc., after its acquisition of RITA, was the exclusive distributor of LC Beads in the United States from 2006 through December 31, 2011.  We are cooperating fully with this investigation and at this time are unable to predict its scope, duration or outcome.
	EndoVention v. AngioDynamics
	On November 21, 2014, EndoVention, Inc. filed a complaint in the United States District Court for the Northern District of California, alleging that our AngioVac products infringe two of EndoVention’s patents. On February 4, 2015, the matter was settled and on March 3, 2015, the case was dismissed with prejudice. The terms of the confidential settlement did not have a material adverse effect on our financial position or results of operations.
	Regulatory Matter
	On November 5, 2014, the Company received a Warning Letter from the FDA relating to observations noted during FDA’s inspection of the Company’s Navilyst Medical facilities located in Marlborough, Massachusetts and Glens Falls, New York in 2014.  The matters raised in the Warning Letter and observations focused on design control processes related to packaging validations and accelerated and real time aging testing in connection with the Company’s fluid management and PICC families of products, inconsistency of a manufacturing product test process used among similar valved PICC products, a particular verification test of valved PICC products and non-conforming product control procedures.  The Company takes these matters seriously and is committed to complying with all applicable laws, regulations and rules in connection with the manufacturing, sale and marketing of its products.  The Company has made a comprehensive response to the issues raised in the letter and is committed to working with the FDA to resolve all outstanding issues. The Company does not expect this matter will have a material adverse effect on its financial position or results of operations.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	9 Months Ended
	Feb. 28, 2015
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
	In May 2014, the FASB and the International Accounting Standards Board (“IASB”) issued their final standard on revenue from contracts with customers. The standard, issued as an ASU by the FASB and as International Financial Reporting Standards 15 by the IASB, outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for the Company in its first quarter beginning January 1, 2017 and is not expected to have a material impact on the Company’s consolidated financial statements.
	In June 2014, the FASB issued an ASU that clarified that entities should treat performance targets that can be met after the requisite service period of a share-based payment award as performance conditions that affect vesting. Therefore, an entity would not record compensation expense related to an award for which transfer to the employee is contingent on the entity’s satisfaction of a performance target until it becomes probable that the performance target is met. This ASU is effective for the Company in its first quarter beginning January 1, 2016 and is not expected to have a material impact on the Company’s consolidated financial statements.

Restructuring

Restructuring	9 Months Ended
	Feb. 28, 2015
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING
	During the three and nine months ended February 28, 2015 we initiated a restructuring of finance, R&D and S&M organizations to improve our profitability. As part of the restructuring, we recorded $(0.1) million and $1.1 million of severance expense, respectively, which is included in “Acquisition, restructuring and other items, net” in the statements of income.

Immaterial_Corrections

Immaterial Corrections	9 Months Ended
	Feb. 28, 2015
Accounting Changes and Error Corrections [Abstract]
Immaterial Corrections	IMMATERIAL ERROR CORRECTIONS
	During the financial closing process for the first quarter of fiscal year 2015, the Company determined that financial management had incorrectly accounted for certain asset, liability and income statement balances, beginning in 2011. The Company has identified amounts and concluded that they were not material individually or in the aggregate to any of its previously issued annual and interim financial statements. Although management has determined the amounts individually and in the aggregate are not material to prior periods, in accordance with authoritative accounting literature on considering the effects of misstatements in prior years when quantifying misstatements in the current year, the financial statements included herein have been adjusted to correct for the impact of these items.
	The Company has corrected the relevant financial information from previous reporting periods contained in these financial statements. The immaterial error corrections identified were primarily related to our failure to recognize the expense associated with prepaid and other assets in accordance with the underlying contractual terms (cumulative impact of approximately $1.2 million) and depreciation expense (cumulative impact of approximately $0.4 million), and other individually immaterial items. Also, approximately $5.4 million of contingent consideration liabilities that had been classified as current are classified as long term in the balance sheet.
	The impacts of these revisions are shown in the tables below:
		Three months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	88,195		$	(45	)	$	88,150
	Cost of sales	43,277			80			43,357
	Gross profit	44,918			(125		)	44,793
	Total operating expenses	38,066			214			38,280
	Operating income	6,852			(339		)	6,513
	Total other income (expense)	(1,985		)	15			(1,970		)
	Income (loss) before taxes	4,867			(324		)	4,543
	Income tax benefit (expense)	(176		)	148			(28		)
	Net income (loss)	4,691			(176		)	4,515
	Total comprehensive income (loss), net of tax	4,869			(176		)	4,693
		Nine months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	260,390		$	(25	)	$	260,365
	Cost of sales	128,060			47			128,107
	Gross profit	132,330			(72		)	132,258
	Total operating expenses	122,617			285			122,902
	Operating income	9,713			(357		)	9,356
	Total other income (expense)	(5,579		)	(147		)	(5,726		)
	Income (loss) before taxes	4,134			(504		)	3,630
	Income tax benefit (expense)	32			219			251
	Net income (loss)	4,166			(285		)	3,881
	Total comprehensive income (loss), net of tax	4,356			(285		)	4,071
	During the quarter ended February 28, 2015, the Company recorded aggregate out of period corrections of $0.4 million, net of tax, which negatively impacted net income (loss) in the period. These corrections were primarily associated with research and development expense that should have been recorded in the first half of fiscal 2015. The Company has determined that these adjustments were not material to any prior annual or interim periods.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Feb. 28, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost (using the first-in, first-out method) or market. As of February 28, 2015 and May 31, 2014, inventories consisted of the following:
		Feb 28, 2015		31-May-14
		(in thousands)
	Raw materials	$	28,155	$	24,734
	Work in process	12,050		11,992
	Finished goods	28,505		24,508
	Inventories	$	68,710	$	61,234

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Feb. 28, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill by Segment	djustments to goodwill for the nine months ended February 28, 2015.
Intangible Assets	As of February 28, 2015 and May 31, 2014, intangible assets consisted of the following:
		28-Feb-15
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	148,776	$	(38,724	)	$	110,052	10.2
	Customer relationships	86,397		(41,770		)	44,627		12
	Trademark-NAMIC	22,200		—			22,200		12
	Licenses	7,913		(5,709		)	2,204		8.7
	Trademarks	6,345		(2,481		)	3,864		8
	In-process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	276,131	$	(89,584	)	$	186,547
		31-May-14
		Gross		Accumulated			Net carrying		Weighted
		carrying		amortization			value		avg useful
		value							life
		(in thousands)							(years)
	Product technologies	$	150,298	$	(32,930	)	$	117,368	10.2
	Customer relationships	86,645		(37,848		)	48,797		11.9
	Trademark-NAMIC	28,600		—			28,600		Indefinite
	Licenses	7,639		(5,211		)	2,428		8.4
	Trademarks	6,345		(1,882		)	4,463		8
	In process R&D acquired	3,600		—			3,600		Indefinite
	Distributor relationships	900		(900		)	—		3
		$	284,027	$	(78,771	)	$	205,256

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Feb. 28, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	As of February 28, 2015 and May 31, 2014, accrued liabilities consisted of the following:
		Feb 28, 2015		31-May-14
		(in thousands)
	Payroll and related expenses	$	10,535	$	8,114
	Royalties	2,149		2,620
	Accrued severance	472		765
	Sales and franchise taxes	697		1,327
	Interest rate swap liability	267		555
	Accrued taxes payable	1,808		371
	Other	4,018		3,499
		$	19,946	$	17,251

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Feb. 28, 2015
Income Tax Disclosure [Abstract]
Components of Income Tax Expense/(Benefit)	The following table presents the components of income tax expense(benefit) for the three and nine months ended February 28, 2015 and 2014 (in thousands of dollars):
		Three Months Ended						Nine Months Ended
		28-Feb-15			28-Feb-14			28-Feb-15			28-Feb-14
	Income (loss) before Income Taxes	$	(11,979	)	$	4,543		$	(7,732	)	$	3,630
	Less discrete book income (expense):
	Non taxable portion of revaluation of contingent consideration	9,229			5,000			9,229			5,000
	Taxable portion of revaluation of contingent consideration	1,323			—			1,323			—
	Morpheus product recall and discontinuance	(6,145		)	—			(6,145		)	—
	Impairment of Automated Power Injector fixed asset	(8,200		)	—			(8,200		)	—
	Impairment of indefinite-lived intangible asset	(6,400		)	—			(6,400		)	—
	Ordinary income (loss) before income taxes	(1,786		)	(457		)	2,461			(1,370		)
	Income tax expense (benefit) based on ordinary income (loss) at estimated tax rates of 51.8% and 42.9% for the three and nine months ended February 28, 2015 and February 28, 2014, respectively	$	(461	)	$	(233	)	$	1,276		$	(587	)
	Discrete tax expense (benefit):
	Morpheus product recall and discontinuance	(2,243		)	—			(2,243		)	—
	Impairment of Automated Power Injector fixed asset	(2,993		)	—			(2,993		)	—
	Taxable gain on revaluation of contingent consideration liability	483			—			483			—
	Impairment of indefinite-lived intangible asset	(2,336		)	—			(2,336		)	—
	Adjustment for elimination of the ASC 718 APIC pool	289			62			974			123
	Retroactive renewal of the Research and Experimentation credit	(519		)	—			(519		)	—
	Adjustment to fully reserved capital losses	—			43			—			43
	Adjustments to prior period tax liabilities	63			156			80			170
	Total income tax expense (benefit)	$	(7,717	)	$	28		$	(5,278	)	$	(251	)
Summary of Operating Loss Carryforwards	loss carryforwards recorded in business acquisitions, which expire as follows:
	Expiration Date	NOL Available (in thousands)
	FY 2017	$	802
	FY 2019	11,898
	FY 2020	8,128
	FY 2022	7,526
	FY 2023	2,346
	FY 2027	20,167
	FY 2028	22,527
	FY 2029	27,684
	FY 2030	28,043
	FY 2031	5,647
	FY 2032	600
	FY 2033	3,389

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Feb. 28, 2015
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding	The following table reconciles basic to diluted weighted-average shares outstanding for the three and nine months ended February 28, 2015 and 2014 (in thousands):
		Three Months Ended		Nine Months Ended
		Feb 28, 2015	Feb 28, 2014	Feb 28, 2015	Feb 28, 2014
	Basic	35,755	35,184	35,568	35,088
	Effect of dilutive securities	—	520	—	284
	Diluted	35,755	35,704	35,568	35,372
	Securities excluded as their inclusion would be anti-dilutive	362	677	674	2,306

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	9 Months Ended
	Feb. 28, 2015
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	The table below summarizes net sales by product category (in thousands of dollars):
		Three Months Ended				Nine Months Ended
		Feb 28, 2015		Feb 28, 2014		Feb 28, 2015		Feb 28, 2014
	Net sales
	Peripheral Vascular	$	46,195	$	47,358	$	142,996	$	141,718
	Vascular Access	26,400		27,259		80,793		78,113
	Oncology/Surgery	13,066		11,968		39,062		35,692
	Supply Agreement	936		1,565		3,226		4,842
	Total	$	86,597	$	88,150	$	266,077	$	260,365
Summary of Net Sales by Geographic Area	The table below presents net sales by geographic area based on external customer location (in thousands of dollars):
		Three Months Ended				Nine Months Ended
		Feb 28, 2015		Feb 28, 2014		Feb 28, 2015		Feb 28, 2014
	Net sales
	United States	$	68,410	$	69,814	$	208,848	$	206,466
	International	17,251		16,771		54,003		49,057
	Supply Agreement	936		1,565		3,226		4,842
	Total	$	86,597	$	88,150	$	266,077	$	260,365

Fair_Value_Tables

Fair Value (Tables)	9 Months Ended
	Feb. 28, 2015
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2015 and May 31, 2014 (in thousands of dollars):
		Fair Value Measurements using								Fair Value at February 28, 2015
		inputs considered as:
		Level 1			Level 2			Level 3
	Financial Assets
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,682	$	1,682
	Total	—			—			1,682		1,682
	Total Financial Assets	$	—		$	—		$	1,682	$	1,682
	Financial Liabilities
	Interest rate swap agreements	$	—		$	267		$	—	$	267
	Contingent liability for acquisition earn out	—			—			47,005		47,005
	Total Financial Liabilities	$	—		$	267		$	47,005	$	47,272
		Fair Value Measurements using								Fair Value at May 31, 2014
		inputs considered as:
		Level 1			Level 2			Level 3
	Financial Assets
	Cash equivalents
	Money market funds	$	445		$	—		$	—	$	445
	Total	$	445		$	—		$	—	$	445
	Marketable securities
	U.S. government agency obligations	$	—		$	—		$	1,809	$	1,809
	Total	—			—			1,809		1,809
	Total Financial Assets	$	445		$	—		$	1,809	$	2,254
	Financial Liabilities
	Interest rate swap agreements	$	—		$	555		$	—	$	555
	Contingent liability for acquisition earn out	—			—			67,331		67,331
	Total Financial Liabilities	$	—		$	555		$	67,331	$	67,886
Fair Value Measurements Using Significant Unobservable Inputs	The table below presents the changes in fair value components of Level 3 instruments in the nine months ended February 28, 2015 (in thousands of dollars):
		Financial Assets			Financial Liabilities
		Fair Value Measurements			Fair Value Measurements
		Using Significant			Using Significant
		Unobservable Inputs			Unobservable Inputs
		(Level 3)			(Level 3)
	Balance, May 31, 2014	$	1,809		$	67,331
	Change in present value of contingent consideration (1)	—			(8,626		)
	Currency (gain) loss from remeasurement	—			(478		)
	Included in other comprehensive income	(127		)	—
	Contingent consideration payments	—			(11,222		)
	Balance, February 28, 2015	$	1,682		$	47,005
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of February 28, 2015 (in thousands of dollars):
		Fair value at			Valuation
		Feb 28, 2015			Technique		Unobservable Input	Range
	Revenue based payments	$	44,383		Discounted cash flow		Discount rate	4%
							Probability of payment	75-100%
							Projected fiscal year of payment	2016 - 2022
	Milestone based payments	2,622			Discounted cash flow		Discount rate	16%
							Probability of payment	75-100%
							Projected fiscal year of payment	2017
	Total	$	47,005

Marketable_Securities_Tables

Marketable Securities (Tables)	9 Months Ended
	Feb. 28, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	As of February 28, 2015 and May 31, 2014, marketable securities consisted of the following (in thousands of dollars):
	As of February 28, 2015	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(143	)	$	1,682
		$	1,825	$	—	$	(143	)	$	1,682
	As of May 31, 2014	Amortized		Gross		Gross			Fair Value
		cost		Unrealized		Unrealized
				Gains		Losses
	Available-for-sales securities
	U.S. government agency obligations	$	1,825	$	—	$	(16	)	$	1,809
		$	1,825	$	—	$	(16	)	$	1,809

Immaterial_Corrections_Tables

Immaterial Corrections (Tables)	9 Months Ended
	Feb. 28, 2015
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The impacts of these revisions are shown in the tables below:
		Three months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	88,195		$	(45	)	$	88,150
	Cost of sales	43,277			80			43,357
	Gross profit	44,918			(125		)	44,793
	Total operating expenses	38,066			214			38,280
	Operating income	6,852			(339		)	6,513
	Total other income (expense)	(1,985		)	15			(1,970		)
	Income (loss) before taxes	4,867			(324		)	4,543
	Income tax benefit (expense)	(176		)	148			(28		)
	Net income (loss)	4,691			(176		)	4,515
	Total comprehensive income (loss), net of tax	4,869			(176		)	4,693
		Nine months ended February 28, 2014
		As previously reported			Adjustments			As revised
	Net sales	$	260,390		$	(25	)	$	260,365
	Cost of sales	128,060			47			128,107
	Gross profit	132,330			(72		)	132,258
	Total operating expenses	122,617			285			122,902
	Operating income	9,713			(357		)	9,356
	Total other income (expense)	(5,579		)	(147		)	(5,726		)
	Income (loss) before taxes	4,134			(504		)	3,630
	Income tax benefit (expense)	32			219			251
	Net income (loss)	4,166			(285		)	3,881
	Total comprehensive income (loss), net of tax	4,356			(285		)	4,071
	During the quarter ended February 28, 2015, the Company recorded aggregate out of period corrections of $0.4 million, net of tax, which negatively impacted net income (loss) in the period. These corrections were primarily associated with research and development expense that should have been recorded in the first half of fiscal 2015. The Company has determined that these adjustments were not material to any prior annual or interim periods.

Consolidated_Financial_Stateme1

Consolidated Financial Statements - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Sep. 19, 2013	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	31-May-12	Apr. 09, 2015
Recent Developments [Line Items]
Ratio for debt service coverage	1.35
Ratio of indebtedness to consolidated EBITDA	3.75
Fixed asset impairment charges		$8,200,000
Trademark impairment		6,400,000	0	6,400,000	0
New Credit Agreement [Member]
Recent Developments [Line Items]
Percentage of increase in interest	2.00%
New Credit Agreement [Member] | Term Loan Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility	100,000,000
Term loan quarterly repayment, year one	5.00%
Term loan quarterly repayment, year two	5.00%
Term loan quarterly repayment, year three	10.00%
Term loan quarterly repayment, year four	15.00%
Term loan quarterly repayment, year five	65.00%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member]
Recent Developments [Line Items]
Senior secured term loan facility	100,000,000
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Minimum [Member]
Recent Developments [Line Items]
Commitment fee, percentage	0.20%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Maximum [Member]
Recent Developments [Line Items]
Commitment fee, percentage	0.35%
New Credit Agreement [Member] | Letters of Credit [Member]
Recent Developments [Line Items]
Senior secured term loan facility	20,000,000
New Credit Agreement [Member] | Swingline Loans [Member]
Recent Developments [Line Items]
Senior secured term loan facility	5,000,000
New Credit Agreement [Member] | Revolving Credit Facility [Member]
Recent Developments [Line Items]
Initial amount borrowed under revolving facility	41,400,000
New Credit Agreement [Member] | Base Rate [Member] | JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] | Eurodollar [Member] | JP Morgan Chase [Member]
Recent Developments [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
Trademarks [Member]
Recent Developments [Line Items]
Trademark impairment		6,400,000		6,400,000
Trademarks [Member] | Navylist [Member]
Recent Developments [Line Items]
Indefinite-lived intangible associated with trademark						28,600,000
Sales [Member]
Recent Developments [Line Items]
Reduction in Net sales		200,000
Cost of Sales [Member]
Recent Developments [Line Items]
Write-off of inventory		5,000,000
Restructuring And Other Items [Member]
Recent Developments [Line Items]
Costs in acquisition, restructuring and other items		900,000		900,000
EmboMedics Inc. [Member] | Subsequent Event [Member]
Recent Developments [Line Items]
Equity investment							2,000,000
Equity investment, additional equity contribution							$9,000,000

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended	1 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	31-May-14	Aug. 15, 2013
Business Acquisition [Line Items]
Goodwill acquired	$360,473,000		$360,473,000
Estimated useful life			3 years
Upfront payment included in total estimated purchase consideration	1,004,000	180,000
Minimum [Member]
Business Acquisition [Line Items]
Estimated useful life	2 years
Maximum [Member]
Business Acquisition [Line Items]
Estimated useful life	15 years
Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Cash payments at closing total				3,700,000
Business acquisition purchase price holdback amount				400,000
Total purchase				8,700,000
Present value of contingent consideration liability				5,000,000
Goodwill acquired				4,800,000
Intangible assets other than goodwill				5,100,000
Deferred tax liability				1,200,000
In Process Research and Development [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Intangible assets other than goodwill				3,600,000
Customer Relationships [Member]
Business Acquisition [Line Items]
Estimated useful life	12 years		11 years 10 months 24 days
Customer Relationships [Member] | Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Estimated useful life				15 years
Customer Relationships [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Finite-Lived Customer Relationships, Gross				1,400,000
Trademarks [Member]
Business Acquisition [Line Items]
Estimated useful life	8 years		8 years
Trademarks [Member] | Clinical Devices B.V [Member]
Business Acquisition [Line Items]
Estimated useful life				5 years
Trademarks [Member] | Clinical Devices, B.V. [Member]
Business Acquisition [Line Items]
Acquired finite lived intangible assets				70,000

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Feb. 28, 2015	31-May-14
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$28,155	$24,734
Work in process	12,050	11,992
Finished goods	28,505	24,508
Inventories	$68,710	$61,234

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	0 Months Ended
	Dec. 31, 2013	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	31-May-14	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill						3 years
Fair Value Inputs, Capitalization Rate		8.00%		8.00%
Fair Value Inputs, Discount Rate				12.00%
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$6,400,000	$0	$6,400,000	$0
Percentage of Fair Value Exceeding Its Carrying Value	18.00%
Goodwill, Impairment Loss	0
Income Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Fair Value Assumptions, Calculation Weighted Applied to Various Valuation Method						75.00%
Fair Value Inputs, Discount Rate							12.00%
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$6,400,000					$6,400,000
Fair Value Inputs, Long-term Revenue Growth Rate							3.00%
Fair Value Inputs Royalty Rate							3.00%
Market Approach Valuation Technique [Member]
Finite-Lived Intangible Assets [Line Items]
Fair Value Assumptions, Calculation Weighted Applied to Various Valuation Method						25.00%
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				15 years
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill				2 years

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Goodwill by Segment (Detail) (USD $)	Feb. 28, 2015	31-May-14	Aug. 15, 2013
In Thousands, unless otherwise specified
Goodwill [Line Items]
Goodwill, Beginning Balance	$360,473	$360,473
Goodwill, Ending Balance	360,473	360,473
Clinical Devices B.V [Member]
Goodwill [Line Items]
Goodwill, Beginning Balance			4,800
Goodwill, Ending Balance			$4,800

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	31-May-14
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, excluding goodwill	$276,131	$284,027
Accumulated amortization	-89,584	-78,771
Net carrying value, excluding goodwill	186,547	205,256
Weighted avg useful life		3 years
Product Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	148,776	150,298
Accumulated amortization	-38,724	-32,930
Net carrying value, finite intangible items	110,052	117,368
Weighted avg useful life	10 years 2 months	10 years 2 months 12 days
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	86,397	86,645
Accumulated amortization	-41,770	-37,848
Net carrying value, finite intangible items	44,627	48,797
Weighted avg useful life	12 years	11 years 10 months 24 days
Trademark NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted avg useful life	12 years
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	7,913	7,639
Accumulated amortization	-5,709	-5,211
Net carrying value, finite intangible items	2,204	4,463
Weighted avg useful life	8 years 8 months	8 years 4 months 24 days
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	6,345	6,345
Accumulated amortization	-2,481	-1,882
Net carrying value, finite intangible items	3,864	3,600
Weighted avg useful life	8 years	8 years
Distributor Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	900	900
Accumulated amortization	-900	-900
Net carrying value, finite intangible items	0	0
Weighted avg useful life	3 years
Trademark NAMIC [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items	22,200	28,600
Accumulated amortization	0	0
Net carrying value, indefinite items	22,200	28,600
In-process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite items	3,600	3,600
Accumulated amortization	0	0
Net carrying value, indefinite items	$3,600	$2,428

Accrued_Liabilities_Summary_of

Accrued Liabilities - Summary of Accrued Liabilities (Detail) (USD $)	Feb. 28, 2015	31-May-14
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Payroll and related expenses	$10,535	$8,114
Royalties	2,149	2,620
Accrued severance	472	765
Accrued taxes payable	697	1,327
Interest rate swap liability	267	555
Other	4,018	3,499
Total	$19,946	$17,251

Long_Term_Debt_Additional_Info

Long Term Debt - Additional Information (Detail) (USD $)	0 Months Ended
	Sep. 19, 2013	Feb. 28, 2015	31-May-14	Sep. 19, 2013
Debt Instrument [Line Items]
Notional amount of interest rate swap agreement	$100,000,000			$100,000,000
Fixed interest rate payments	0.74%			0.74%
Long-term debt, net of current portion		141,410,000	137,660,000
Ratio for debt service coverage	1.35
Ratio of indebtedness to consolidated EBITDA	3.75			3.75
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt, net of current portion	56,400,000			56,400,000
New Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of increase in interest	2.00%
New Credit Agreement [Member] | Base Rate [Member] | JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	0.50%
Percentage of increases leverage ratio base rate, maximum	1.25%
New Credit Agreement [Member] | Eurodollar [Member] | JP Morgan Chase [Member]
Debt Instrument [Line Items]
Percentage of increases leverage ratio base rate, minimum	1.50%
Percentage of increases leverage ratio base rate, maximum	2.25%
New Credit Agreement [Member] | Term Loan Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100,000,000			100,000,000
Term loan quarterly repayment, year one	5.00%
Term loan quarterly repayment, year two	5.00%
Term loan quarterly repayment, year three	10.00%
Term loan quarterly repayment, year four	15.00%
Term loan quarterly repayment, year five	65.00%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	100,000,000			100,000,000
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.20%
New Credit Agreement [Member] | Senior Secured Revolving Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.35%
New Credit Agreement [Member] | Letters of Credit [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	20,000,000			20,000,000
New Credit Agreement [Member] | Swingline Loans [Member]
Debt Instrument [Line Items]
Senior secured term loan facility	5,000,000			5,000,000
New Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Initial amount borrowed under revolving facility	41,400,000			41,400,000
Term Loan [Member]
Debt Instrument [Line Items]
Long-term debt, net of current portion	$92,500,000			$92,500,000

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense/(Benefit) (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Income Tax Disclosure [Abstract]
Income (loss) before income tax expense (benefit)	($11,979)	$4,543	($7,732)	$3,630
Non taxable portion of revaluation of contingent consideration	9,229	5,000	9,229	5,000
Taxable portion of revaluation of contingent consideration	1,323	0	1,323	0
Morpheus product recall and discontinuance	-6,145	0	-6,145	0
Impairment of Automated Power Injector fixed asset	-8,200	0	-8,200	0
Impairment of indefinite-lived intangible asset	-6,400	0	-6,400	0
Ordinary income (loss) before income taxes	-1,786	-457	2,461	-1,370
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount [Abstract]
Income tax expense / (benefit) based on ordinary income / (loss) at estimated tax rates	-461	-233	1,276	-587
Discrete tax expense (benefit):
Morpheus product recall and discontinuance	-2,243	0	-2,243	0
Impairment of Automated Power Injector fixed asset	-2,993	0	-2,993	0
Taxable gain on revaluation of contingent consideration liability	483	0	483	0
Impairment of indefinite-lived intangible asset	-2,336	0	-2,336	0
Adjustment for elimination of the ASC 718 APIC pool	289	62	974	123
Retroactive renewal of the Research and Experimentation credit	-519	0	-519	0
Adjustment to fully reserved capital losses	0	43	0	43
Adjustments to prior period tax liabilities	63	156	80	170
Total income tax expense (benefit)	($7,717)	$28	($5,278)	($251)

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Income Tax Examination [Line Items]
Estimated federal statutory income tax rate	51.80%	42.90%	51.80%	42.90%
Federal statutory income tax rate			35.00%
Loss carryforwards from acquisitions	$139,000,000		$139,000,000
Domestic Tax Authority [Member]
Income Tax Examination [Line Items]
Net deferred tax asset	$19,100,000		$19,100,000

Income_Taxes_Net_Operating_Los

Income Taxes Net Operating Loss Carryforwards (Details) (USD $)	Feb. 28, 2015
In Thousands, unless otherwise specified
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	$139,000
FY 2017
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	802
FY 2019
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	11,898
FY 2020
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	8,128
FY 2022
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	7,526
FY 2023
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	2,346
FY 2027
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	20,167
FY 2028
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	22,527
FY 2029
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	27,684
FY 2030
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	28,043
FY 2031
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	5,647
FY 2032
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	600
FY 2033
Operating Loss Carryforwards [Line Items]
Loss carryforwards from acquisitions	$3,389

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Amount of shares issuable through two stock-based compensation plans	5.8
Charges against income for share-based payment arrangements	$1.50	$1.60
Unrecognized compensation expenses related to share-based payment arrangements	$12.10

Earnings_Per_Share_Reconciliat

Earnings Per Share - Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Earnings Per Share [Abstract]
Basic	35,755	35,184	35,568	35,088
Effect of dilutive securities	0	520	0	284
Diluted	35,755	35,704	35,568	35,372

Segment_and_Geographic_Informa2

Segment and Geographic Information - Additional Information (Detail)	9 Months Ended
	Feb. 28, 2014
	Segment
Segment Reporting [Abstract]
Number of segment	1

Segment_and_Geographic_Informa3

Segment and Geographic Information - Summary of Net Sales by Product Category (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Segment Reporting Information [Line Items]
Net sales	$86,597	$88,150	$266,077	$260,365
Peripheral Vascular [Member]
Segment Reporting Information [Line Items]
Net sales	46,195	47,358	142,996	141,718
Vascular Access [Member]
Segment Reporting Information [Line Items]
Net sales	26,400	27,259	80,793	78,113
Oncology/Surgery [Member]
Segment Reporting Information [Line Items]
Net sales	13,066	11,968	39,062	35,692
Supply Agreement [Member]
Segment Reporting Information [Line Items]
Net sales	$936	$1,565	$3,226	$4,842

Segment_and_Geographic_Informa4

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014
Net Sales
Net sales	$86,597	$88,150	$266,077	$260,365
Supply Agreement [Member]
Net Sales
Net sales	936	1,565	3,226	4,842
Reportable Geographical Components [Member] | United States [Member]
Net Sales
Net sales	68,410	69,814	208,848	206,466
Reportable Geographical Components [Member] | International [Member]
Net Sales
Net sales	17,251	16,771	54,003	49,057
Reportable Geographical Components [Member] | Supply Agreement [Member]
Net Sales
Net sales	$936	$1,565	$3,226	$4,842

Fair_Value_Additional_Informat

Fair Value - Additional Information (Detail) (USD $)	Feb. 28, 2015
In Millions, unless otherwise specified
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$54.20

Fair_Value_Fair_Value_of_Asset

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Detail) (USD $)	Feb. 28, 2015	31-May-14
In Thousands, unless otherwise specified
Recurring [Member]
Financial Assets
Cash equivalents		$445
Marketable securities	1,682	1,809
Total Financial Assets	1,682	2,254
Financial Liabilities
Total Financial Liabilities	47,272	67,886
Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents		445
Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,682	1,809
Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	267	555
Contingent Consideration Earn Out Liability [Member]
Financial Liabilities
Total Financial Liabilities	47,005
Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities		67,331
Level 1 [Member] | Recurring [Member]
Financial Assets
Cash equivalents		445
Marketable securities	0	0
Total Financial Assets	0	445
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents		445
Level 1 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 1 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 1 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 2 [Member] | Recurring [Member]
Financial Assets
Cash equivalents		0
Marketable securities	0	0
Total Financial Assets	0	0
Financial Liabilities
Total Financial Liabilities	267	555
Level 2 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents		0
Level 2 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	0	0
Level 2 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	267	555
Level 2 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0
Level 3 [Member] | Recurring [Member]
Financial Assets
Cash equivalents		0
Marketable securities	1,682	1,809
Total Financial Assets	1,682	1,809
Financial Liabilities
Total Financial Liabilities	47,005	67,331
Level 3 [Member] | Recurring [Member] | Money Market Funds [Member]
Financial Assets
Cash equivalents		0
Level 3 [Member] | Recurring [Member] | U.S. Government Agency Obligations [Member]
Financial Assets
Marketable securities	1,682	1,809
Level 3 [Member] | Interest Rate Swap Agreements [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	0	0
Level 3 [Member] | Contingent Consideration Earn Out Liability [Member] | Recurring [Member]
Financial Liabilities
Total Financial Liabilities	$47,005	$67,331

Fair_Value_Fair_Value_Measurem

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets, begining balance	$1,809
Financial liabilities, begining balance	67,331
Currency translation adjustment, assets	0
Currency translation adjustment, liabilities	-478
Included in other comprehensive income, assets	127
Included in other comprehensive income, liabilities	0
Contingent consideration - Clinical Devices, assets	0
Financial assets, ending balance	1,682
Financial liabilities, ending balance	47,005
Clinical Devices B.V [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration - Clinical Devices, liabilities	($11,222)

Fair_Value_Summary_Showing_the

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	31-May-14
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	47,005	$67,331
Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	47,005
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	47,272	67,886
Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities		67,331
Level 3 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	47,005	67,331
Level 3 [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total fair value financial liabilities	47,005	67,331
Level 3 [Member] | Revenue Based Payments [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	44,383
Level 3 [Member] | Revenue Based Payments [Member] | Minimum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	4.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] | Revenue Based Payments [Member] | Maximum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	10.00%
Probability of payment	100.00%
Projected fiscal year of payment	2022
Level 3 [Member] | Milestone Based Payments [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
30-Nov-14	2,622
Level 3 [Member] | Milestone Based Payments [Member] | Minimum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	16.00%
Probability of payment	75.00%
Projected fiscal year of payment	2015
Level 3 [Member] | Milestone Based Payments [Member] | Maximum [Member] | Recurring [Member] | Contingent Consideration Earn Out Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount rate	20.00%
Probability of payment	100.00%
Projected fiscal year of payment	2017

Fair_Value_Summary_Showing_Rec

Fair Value - Summary Showing Reconciliation of the Contingent Payments (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2015	31-May-14
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Currency Translation Adjustment	($478)
30-Nov-14	$47,005	$67,331

Marketable_Securities_Addition

Marketable Securities - Additional Information (Detail) (USD $)	Feb. 28, 2015	31-May-14
In Millions, unless otherwise specified	Investment
Marketable Securities [Abstract]
Investments in auction rate securities that failed auctions	$1.70	$1.80
Number of investments	2

Marketable_Securities_Marketab

Marketable Securities - Marketable Securities (Detail) (USD $)	Feb. 28, 2015	31-May-14
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$1,825	$1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-143	-16
Fair Value	1,682	1,809
U.S. Government Agency Obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	1,825	1,825
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-143	-16
Fair Value	$1,682	$1,809

Commitments_and_Continfencies_

Commitments and Continfencies - Additional Information (Detail) (USD $)	0 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Mar. 18, 2014	Nov. 08, 2012	Jan. 02, 2008	Feb. 28, 2015
			Lawsuit	patent_claim
				Petition
Loss Contingencies [Line Items]
Litigation settlement amount	$74.90
Biolitec [Member]
Loss Contingencies [Line Items]
Number of lawsuits against biolitec previously settled for which seeking defense and indemnification			2
Partial judgment granted		$23.20
C.R. Bard, Inc. [Member]
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents				3
Patent claims				41,000
Rejected patent claims				40,000

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2015
Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Severance expense	$0.10
Selling and Marketing Expense [Member]
Restructuring Cost and Reserve [Line Items]
Severance expense	$1.10

Immaterial_Corrections_Details

Immaterial Corrections (Details) (USD $)	3 Months Ended		9 Months Ended
	Feb. 28, 2015	Feb. 28, 2014	Feb. 28, 2015	Feb. 28, 2014	31-May-14	31-May-13
Net sales	$86,597,000	$88,150,000	$266,077,000	$260,365,000
Cost of sales	48,746,000	43,357,000	134,745,000	128,107,000
Gross profit	37,851,000	44,793,000	131,332,000	132,258,000
Total operating expenses	48,002,000	38,280,000	133,666,000	122,902,000
Operating income	-10,151,000	6,513,000	-2,334,000	9,356,000
Total other income (expenses)	-1,828,000	-1,970,000	-5,398,000	-5,726,000
Income (loss) before taxes	-11,979,000	4,543,000	-7,732,000	3,630,000
Income tax expense (benefit)	7,717,000	-28,000	5,278,000	251,000
Net income (loss)	-4,262,000	4,515,000	-2,454,000	3,881,000
Cash and cash equivalents	19,704,000	7,382,000	19,704,000	7,382,000	16,105,000	21,802,000
Accounts receivable, net of allowances	57,770,000		57,770,000		61,968,000
Inventories	68,710,000		68,710,000		61,234,000
Prepaid expenses and other	4,859,000		4,859,000		5,471,000
Total current assets	157,292,000		157,292,000		151,722,000
Property, plant and equipment - at cost, net	58,295,000		58,295,000		66,590,000
Other assets	4,060,000		4,060,000		4,447,000
Goodwill	360,473,000		360,473,000		360,473,000
Deferred income taxes, long-term	16,469,000		16,469,000		10,403,000
Total assets	783,136,000		783,136,000		798,891,000
Accrued liabilities	19,946,000		19,946,000		17,251,000
Total current liabilities	59,687,000		59,687,000		66,753,000
Total liabilities	239,380,000		239,380,000		262,056,000
Additional paid-in capital	518,349,000		518,349,000		508,354,000
Retained earnings	29,047,000		29,047,000		31,501,000
Total stockholders' equity	543,756,000		543,756,000		536,835,000
Intangible assets, net	186,547,000		186,547,000		205,256,000
Accounts payable	21,696,000		21,696,000		32,895,000
Total comprehensive income (loss), net of tax	-4,813,000	4,693,000	-3,081,000	4,071,000
Research and development	6,855,000	7,045,000	19,642,000	20,757,000
Scenario, Adjustment [Member]
Errors in prepaid assets	1,200,000		1,200,000
Errors in depreciation			400,000
Net sales		-45,000		-25,000
Cost of sales		80,000		47,000
Gross profit		-125,000		-72,000
Total operating expenses		214,000		285,000
Operating income		-339,000		-357,000
Total other income (expenses)		15,000		-147,000
Income (loss) before taxes		-324,000		-504,000
Income tax expense (benefit)		148,000		219,000
Net income (loss)		-176,000		-285,000
Total comprehensive income (loss), net of tax		-176,000		-285,000
Scenario, Previously Reported [Member]
Net sales		88,195,000		260,390,000
Cost of sales		43,277,000		128,060,000
Gross profit		44,918,000		132,330,000
Total operating expenses		38,066,000		122,617,000
Operating income		6,852,000		9,713,000
Total other income (expenses)		-1,985,000		-5,579,000
Income (loss) before taxes		4,867,000		4,134,000
Income tax expense (benefit)		-176,000		32,000
Net income (loss)		4,691,000		4,166,000
Total comprehensive income (loss), net of tax		4,869,000		4,356,000
Restatement Adjustment [Member]
Contingent consideration liabilities reclassified as long term from current	5,400,000		5,400,000
Research and development	$400,000